Table of Content

1 Non-Insulin Hypoglycemic Drug Market Overview
1.1 Product Overview and Scope of Non-Insulin Hypoglycemic Drug
1.2 Non-Insulin Hypoglycemic Drug Segment by Type
1.2.1 Global Non-Insulin Hypoglycemic Drug Market Value Comparison by Type (2024-2034)
1.2.2 Sulfonylureas
1.2.3 Meglitinides
1.2.4 Biguanides
1.2.5 Thiazolidinediones
1.2.6 Alpha Glucosidase Inhibitors
1.2.7 Others
1.3 Non-Insulin Hypoglycemic Drug Segment by Application
1.3.1 Global Non-Insulin Hypoglycemic Drug Market Value by Application: (2024-2034)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.4 Global Non-Insulin Hypoglycemic Drug Market Size Estimates and Forecasts
1.4.1 Global Non-Insulin Hypoglycemic Drug Revenue 2024-2034
1.4.2 Global Non-Insulin Hypoglycemic Drug Sales 2024-2034
1.4.3 Global Non-Insulin Hypoglycemic Drug Market Average Price (2024-2034)
1.5 Assumptions and Limitations
2 Non-Insulin Hypoglycemic Drug Market Competition by Manufacturers
2.1 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Manufacturers (2024-2024)
2.2 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Manufacturers (2024-2024)
2.3 Global Non-Insulin Hypoglycemic Drug Average Price by Manufacturers (2024-2024)
2.4 Global Non-Insulin Hypoglycemic Drug Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Non-Insulin Hypoglycemic Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Non-Insulin Hypoglycemic Drug, Product Type & Application
2.7 Non-Insulin Hypoglycemic Drug Market Competitive Situation and Trends
2.7.1 Non-Insulin Hypoglycemic Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Non-Insulin Hypoglycemic Drug Players Market Share by Revenue
2.7.3 Global Non-Insulin Hypoglycemic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Non-Insulin Hypoglycemic Drug Retrospective Market Scenario by Region
3.1 Global Non-Insulin Hypoglycemic Drug Market Size by Region: 2024 Versus 2022 Versus 2034
3.2 Global Non-Insulin Hypoglycemic Drug Global Non-Insulin Hypoglycemic Drug Sales by Region: 2024-2034
3.2.1 Global Non-Insulin Hypoglycemic Drug Sales by Region: 2024-2024
3.2.2 Global Non-Insulin Hypoglycemic Drug Sales by Region: 2024-2034
3.3 Global Non-Insulin Hypoglycemic Drug Global Non-Insulin Hypoglycemic Drug Revenue by Region: 2024-2034
3.3.1 Global Non-Insulin Hypoglycemic Drug Revenue by Region: 2024-2024
3.3.2 Global Non-Insulin Hypoglycemic Drug Revenue by Region: 2024-2034
3.4 North America Non-Insulin Hypoglycemic Drug Market Facts & Figures by Country
3.4.1 North America Non-Insulin Hypoglycemic Drug Market Size by Country: 2024 VS 2022 VS 2034
3.4.2 North America Non-Insulin Hypoglycemic Drug Sales by Country (2024-2034)
3.4.3 North America Non-Insulin Hypoglycemic Drug Revenue by Country (2024-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Non-Insulin Hypoglycemic Drug Market Facts & Figures by Country
3.5.1 Europe Non-Insulin Hypoglycemic Drug Market Size by Country: 2024 VS 2022 VS 2034
3.5.2 Europe Non-Insulin Hypoglycemic Drug Sales by Country (2024-2034)
3.5.3 Europe Non-Insulin Hypoglycemic Drug Revenue by Country (2024-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Non-Insulin Hypoglycemic Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Non-Insulin Hypoglycemic Drug Market Size by Country: 2024 VS 2022 VS 2034
3.6.2 Asia Pacific Non-Insulin Hypoglycemic Drug Sales by Country (2024-2034)
3.6.3 Asia Pacific Non-Insulin Hypoglycemic Drug Revenue by Country (2024-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Non-Insulin Hypoglycemic Drug Market Facts & Figures by Country
3.7.1 Latin America Non-Insulin Hypoglycemic Drug Market Size by Country: 2024 VS 2022 VS 2034
3.7.2 Latin America Non-Insulin Hypoglycemic Drug Sales by Country (2024-2034)
3.7.3 Latin America Non-Insulin Hypoglycemic Drug Revenue by Country (2024-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Non-Insulin Hypoglycemic Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Non-Insulin Hypoglycemic Drug Market Size by Country: 2024 VS 2022 VS 2034
3.8.2 Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Country (2024-2034)
3.8.3 Middle East and Africa Non-Insulin Hypoglycemic Drug Revenue by Country (2024-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Non-Insulin Hypoglycemic Drug Sales by Type (2024-2034)
4.1.1 Global Non-Insulin Hypoglycemic Drug Sales by Type (2024-2024)
4.1.2 Global Non-Insulin Hypoglycemic Drug Sales by Type (2024-2034)
4.1.3 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2024-2034)
4.2 Global Non-Insulin Hypoglycemic Drug Revenue by Type (2024-2034)
4.2.1 Global Non-Insulin Hypoglycemic Drug Revenue by Type (2024-2024)
4.2.2 Global Non-Insulin Hypoglycemic Drug Revenue by Type (2024-2034)
4.2.3 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2024-2034)
4.3 Global Non-Insulin Hypoglycemic Drug Price by Type (2024-2034)
5 Segment by Application
5.1 Global Non-Insulin Hypoglycemic Drug Sales by Application (2024-2034)
5.1.1 Global Non-Insulin Hypoglycemic Drug Sales by Application (2024-2024)
5.1.2 Global Non-Insulin Hypoglycemic Drug Sales by Application (2024-2034)
5.1.3 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2024-2034)
5.2 Global Non-Insulin Hypoglycemic Drug Revenue by Application (2024-2034)
5.2.1 Global Non-Insulin Hypoglycemic Drug Revenue by Application (2024-2024)
5.2.2 Global Non-Insulin Hypoglycemic Drug Revenue by Application (2024-2034)
5.2.3 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2024-2034)
5.3 Global Non-Insulin Hypoglycemic Drug Price by Application (2024-2034)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Corporation Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.1.4 GSK Non-Insulin Hypoglycemic Drug Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Eli Lilly
6.2.1 Eli Lilly Corporation Information
6.2.2 Eli Lilly Description and Business Overview
6.2.3 Eli Lilly Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.2.4 Eli Lilly Non-Insulin Hypoglycemic Drug Product Portfolio
6.2.5 Eli Lilly Recent Developments/Updates
6.3 Sumitomo Dainippon Pharma
6.3.1 Sumitomo Dainippon Pharma Corporation Information
6.3.2 Sumitomo Dainippon Pharma Description and Business Overview
6.3.3 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.3.4 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Portfolio
6.3.5 Sumitomo Dainippon Pharma Recent Developments/Updates
6.4 Intarcia Therapeutics
6.4.1 Intarcia Therapeutics Corporation Information
6.4.2 Intarcia Therapeutics Description and Business Overview
6.4.3 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Portfolio
6.4.5 Intarcia Therapeutics Recent Developments/Updates
6.5 Servier
6.5.1 Servier Corporation Information
6.5.2 Servier Description and Business Overview
6.5.3 Servier Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.5.4 Servier Non-Insulin Hypoglycemic Drug Product Portfolio
6.5.5 Servier Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.6.4 Pfizer Non-Insulin Hypoglycemic Drug Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Merck Non-Insulin Hypoglycemic Drug Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 Dong-A Pharmaceutical
6.8.1 Dong-A Pharmaceutical Corporation Information
6.8.2 Dong-A Pharmaceutical Description and Business Overview
6.8.3 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.8.4 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio
6.8.5 Dong-A Pharmaceutical Recent Developments/Updates
6.9 Luye Pharma Group
6.9.1 Luye Pharma Group Corporation Information
6.9.2 Luye Pharma Group Description and Business Overview
6.9.3 Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.9.4 Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Portfolio
6.9.5 Luye Pharma Group Recent Developments/Updates
6.10 Eurofarma
6.10.1 Eurofarma Corporation Information
6.10.2 Eurofarma Description and Business Overview
6.10.3 Eurofarma Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.10.4 Eurofarma Non-Insulin Hypoglycemic Drug Product Portfolio
6.10.5 Eurofarma Recent Developments/Updates
6.11 Geropharm
6.11.1 Geropharm Corporation Information
6.11.2 Geropharm Non-Insulin Hypoglycemic Drug Description and Business Overview
6.11.3 Geropharm Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.11.4 Geropharm Non-Insulin Hypoglycemic Drug Product Portfolio
6.11.5 Geropharm Recent Developments/Updates
6.12 Alkem Labs
6.12.1 Alkem Labs Corporation Information
6.12.2 Alkem Labs Non-Insulin Hypoglycemic Drug Description and Business Overview
6.12.3 Alkem Labs Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.12.4 Alkem Labs Non-Insulin Hypoglycemic Drug Product Portfolio
6.12.5 Alkem Labs Recent Developments/Updates
6.13 Jiangsu Hansoh Pharmaceutical
6.13.1 Jiangsu Hansoh Pharmaceutical Corporation Information
6.13.2 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Description and Business Overview
6.13.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.13.4 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio
6.13.5 Jiangsu Hansoh Pharmaceutical Recent Developments/Updates
6.14 Novo Nordisk
6.14.1 Novo Nordisk Corporation Information
6.14.2 Novo Nordisk Non-Insulin Hypoglycemic Drug Description and Business Overview
6.14.3 Novo Nordisk Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.14.4 Novo Nordisk Non-Insulin Hypoglycemic Drug Product Portfolio
6.14.5 Novo Nordisk Recent Developments/Updates
6.15 Emisphere
6.15.1 Emisphere Corporation Information
6.15.2 Emisphere Non-Insulin Hypoglycemic Drug Description and Business Overview
6.15.3 Emisphere Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.15.4 Emisphere Non-Insulin Hypoglycemic Drug Product Portfolio
6.15.5 Emisphere Recent Developments/Updates
6.16 Uni-Bio Science Group
6.16.1 Uni-Bio Science Group Corporation Information
6.16.2 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Description and Business Overview
6.16.3 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.16.4 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Portfolio
6.16.5 Uni-Bio Science Group Recent Developments/Updates
6.17 Takeda
6.17.1 Takeda Corporation Information
6.17.2 Takeda Non-Insulin Hypoglycemic Drug Description and Business Overview
6.17.3 Takeda Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.17.4 Takeda Non-Insulin Hypoglycemic Drug Product Portfolio
6.17.5 Takeda Recent Developments/Updates
6.18 3SBio
6.18.1 3SBio Corporation Information
6.18.2 3SBio Non-Insulin Hypoglycemic Drug Description and Business Overview
6.18.3 3SBio Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.18.4 3SBio Non-Insulin Hypoglycemic Drug Product Portfolio
6.18.5 3SBio Recent Developments/Updates
6.19 Jiangsu Hengrui Medicine
6.19.1 Jiangsu Hengrui Medicine Corporation Information
6.19.2 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Description and Business Overview
6.19.3 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2024-2024)
6.19.4 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Portfolio
6.19.5 Jiangsu Hengrui Medicine Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Non-Insulin Hypoglycemic Drug Industry Chain Analysis
7.2 Non-Insulin Hypoglycemic Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Non-Insulin Hypoglycemic Drug Production Mode & Process
7.4 Non-Insulin Hypoglycemic Drug Sales and Marketing
7.4.1 Non-Insulin Hypoglycemic Drug Sales Channels
7.4.2 Non-Insulin Hypoglycemic Drug Distributors
7.5 Non-Insulin Hypoglycemic Drug Customers
8 Non-Insulin Hypoglycemic Drug Market Dynamics
8.1 Non-Insulin Hypoglycemic Drug Industry Trends
8.2 Non-Insulin Hypoglycemic Drug Market Drivers
8.3 Non-Insulin Hypoglycemic Drug Market Challenges
8.4 Non-Insulin Hypoglycemic Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Non-Insulin Hypoglycemic Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Non-Insulin Hypoglycemic Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Non-Insulin Hypoglycemic Drug Market Competitive Situation by Manufacturers in 2022
Table 4. Global Non-Insulin Hypoglycemic Drug Sales (K Units) of Key Manufacturers (2024-2024)
Table 5. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Manufacturers (2024-2024)
Table 6. Global Non-Insulin Hypoglycemic Drug Revenue (US$ Million) by Manufacturers (2024-2024)
Table 7. Global Non-Insulin Hypoglycemic Drug Revenue Share by Manufacturers (2024-2024)
Table 8. Global Market Non-Insulin Hypoglycemic Drug Average Price (US$/Unit) of Key Manufacturers (2024-2024)
Table 9. Global Key Players of Non-Insulin Hypoglycemic Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Non-Insulin Hypoglycemic Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Non-Insulin Hypoglycemic Drug, Product Type & Application
Table 12. Global Key Manufacturers of Non-Insulin Hypoglycemic Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Non-Insulin Hypoglycemic Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Insulin Hypoglycemic Drug as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Non-Insulin Hypoglycemic Drug Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 17. Global Non-Insulin Hypoglycemic Drug Sales by Region (2024-2024) & (K Units)
Table 18. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2024-2024)
Table 19. Global Non-Insulin Hypoglycemic Drug Sales by Region (2024-2034) & (K Units)
Table 20. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2024-2034)
Table 21. Global Non-Insulin Hypoglycemic Drug Revenue by Region (2024-2024) & (US$ Million)
Table 22. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2024-2024)
Table 23. Global Non-Insulin Hypoglycemic Drug Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2024-2034)
Table 25. North America Non-Insulin Hypoglycemic Drug Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 26. North America Non-Insulin Hypoglycemic Drug Sales by Country (2024-2024) & (K Units)
Table 27. North America Non-Insulin Hypoglycemic Drug Sales by Country (2024-2034) & (K Units)
Table 28. North America Non-Insulin Hypoglycemic Drug Revenue by Country (2024-2024) & (US$ Million)
Table 29. North America Non-Insulin Hypoglycemic Drug Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Non-Insulin Hypoglycemic Drug Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 31. Europe Non-Insulin Hypoglycemic Drug Sales by Country (2024-2024) & (K Units)
Table 32. Europe Non-Insulin Hypoglycemic Drug Sales by Country (2024-2034) & (K Units)
Table 33. Europe Non-Insulin Hypoglycemic Drug Revenue by Country (2024-2024) & (US$ Million)
Table 34. Europe Non-Insulin Hypoglycemic Drug Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Non-Insulin Hypoglycemic Drug Revenue by Region: 2024 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific Non-Insulin Hypoglycemic Drug Sales by Region (2024-2024) & (K Units)
Table 37. Asia Pacific Non-Insulin Hypoglycemic Drug Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Non-Insulin Hypoglycemic Drug Revenue by Region (2024-2024) & (US$ Million)
Table 39. Asia Pacific Non-Insulin Hypoglycemic Drug Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Non-Insulin Hypoglycemic Drug Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America Non-Insulin Hypoglycemic Drug Sales by Country (2024-2024) & (K Units)
Table 42. Latin America Non-Insulin Hypoglycemic Drug Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Non-Insulin Hypoglycemic Drug Revenue by Country (2024-2024) & (US$ Million)
Table 44. Latin America Non-Insulin Hypoglycemic Drug Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Country (2024-2024) & (K Units)
Table 47. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue by Country (2024-2024) & (US$ Million)
Table 49. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Non-Insulin Hypoglycemic Drug Sales (K Units) by Type (2024-2024)
Table 51. Global Non-Insulin Hypoglycemic Drug Sales (K Units) by Type (2024-2034)
Table 52. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2024-2024)
Table 53. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2024-2034)
Table 54. Global Non-Insulin Hypoglycemic Drug Revenue (US$ Million) by Type (2024-2024)
Table 55. Global Non-Insulin Hypoglycemic Drug Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2024-2024)
Table 57. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2024-2034)
Table 58. Global Non-Insulin Hypoglycemic Drug Price (US$/Unit) by Type (2024-2024)
Table 59. Global Non-Insulin Hypoglycemic Drug Price (US$/Unit) by Type (2024-2034)
Table 60. Global Non-Insulin Hypoglycemic Drug Sales (K Units) by Application (2024-2024)
Table 61. Global Non-Insulin Hypoglycemic Drug Sales (K Units) by Application (2024-2034)
Table 62. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2024-2024)
Table 63. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2024-2034)
Table 64. Global Non-Insulin Hypoglycemic Drug Revenue (US$ Million) by Application (2024-2024)
Table 65. Global Non-Insulin Hypoglycemic Drug Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2024-2024)
Table 67. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2024-2034)
Table 68. Global Non-Insulin Hypoglycemic Drug Price (US$/Unit) by Application (2024-2024)
Table 69. Global Non-Insulin Hypoglycemic Drug Price (US$/Unit) by Application (2024-2034)
Table 70. GSK Corporation Information
Table 71. GSK Description and Business Overview
Table 72. GSK Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 73. GSK Non-Insulin Hypoglycemic Drug Product
Table 74. GSK Recent Developments/Updates
Table 75. Eli Lilly Corporation Information
Table 76. Eli Lilly Description and Business Overview
Table 77. Eli Lilly Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 78. Eli Lilly Non-Insulin Hypoglycemic Drug Product
Table 79. Eli Lilly Recent Developments/Updates
Table 80. Sumitomo Dainippon Pharma Corporation Information
Table 81. Sumitomo Dainippon Pharma Description and Business Overview
Table 82. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 83. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product
Table 84. Sumitomo Dainippon Pharma Recent Developments/Updates
Table 85. Intarcia Therapeutics Corporation Information
Table 86. Intarcia Therapeutics Description and Business Overview
Table 87. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 88. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product
Table 89. Intarcia Therapeutics Recent Developments/Updates
Table 90. Servier Corporation Information
Table 91. Servier Description and Business Overview
Table 92. Servier Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 93. Servier Non-Insulin Hypoglycemic Drug Product
Table 94. Servier Recent Developments/Updates
Table 95. Pfizer Corporation Information
Table 96. Pfizer Description and Business Overview
Table 97. Pfizer Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 98. Pfizer Non-Insulin Hypoglycemic Drug Product
Table 99. Pfizer Recent Developments/Updates
Table 100. Merck Corporation Information
Table 101. Merck Description and Business Overview
Table 102. Merck Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 103. Merck Non-Insulin Hypoglycemic Drug Product
Table 104. Merck Recent Developments/Updates
Table 105. Dong-A Pharmaceutical Corporation Information
Table 106. Dong-A Pharmaceutical Description and Business Overview
Table 107. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 108. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product
Table 109. Dong-A Pharmaceutical Recent Developments/Updates
Table 110. Luye Pharma Group Corporation Information
Table 111. Luye Pharma Group Description and Business Overview
Table 112. Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 113. Luye Pharma Group Non-Insulin Hypoglycemic Drug Product
Table 114. Luye Pharma Group Recent Developments/Updates
Table 115. Eurofarma Corporation Information
Table 116. Eurofarma Description and Business Overview
Table 117. Eurofarma Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 118. Eurofarma Non-Insulin Hypoglycemic Drug Product
Table 119. Eurofarma Recent Developments/Updates
Table 120. Geropharm Corporation Information
Table 121. Geropharm Description and Business Overview
Table 122. Geropharm Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 123. Geropharm Non-Insulin Hypoglycemic Drug Product
Table 124. Geropharm Recent Developments/Updates
Table 125. Alkem Labs Corporation Information
Table 126. Alkem Labs Description and Business Overview
Table 127. Alkem Labs Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 128. Alkem Labs Non-Insulin Hypoglycemic Drug Product
Table 129. Alkem Labs Recent Developments/Updates
Table 130. Jiangsu Hansoh Pharmaceutical Corporation Information
Table 131. Jiangsu Hansoh Pharmaceutical Description and Business Overview
Table 132. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 133. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product
Table 134. Jiangsu Hansoh Pharmaceutical Recent Developments/Updates
Table 135. Novo Nordisk Corporation Information
Table 136. Novo Nordisk Description and Business Overview
Table 137. Novo Nordisk Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 138. Novo Nordisk Non-Insulin Hypoglycemic Drug Product
Table 139. Novo Nordisk Recent Developments/Updates
Table 140. Emisphere Corporation Information
Table 141. Emisphere Description and Business Overview
Table 142. Emisphere Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 143. Emisphere Non-Insulin Hypoglycemic Drug Product
Table 144. Emisphere Recent Developments/Updates
Table 145. Uni-Bio Science Group Corporation Information
Table 146. Uni-Bio Science Group Description and Business Overview
Table 147. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 148. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product
Table 149. Uni-Bio Science Group Recent Developments/Updates
Table 150. Takeda Corporation Information
Table 151. Takeda Description and Business Overview
Table 152. Takeda Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 153. Takeda Non-Insulin Hypoglycemic Drug Product
Table 154. Takeda Recent Developments/Updates
Table 155. 3SBio Corporation Information
Table 156. 3SBio Description and Business Overview
Table 157. 3SBio Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 158. 3SBio Non-Insulin Hypoglycemic Drug Product
Table 159. 3SBio Recent Developments/Updates
Table 160. Jiangsu Hengrui Medicine Corporation Information
Table 161. Jiangsu Hengrui Medicine Description and Business Overview
Table 162. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 163. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product
Table 164. Jiangsu Hengrui Medicine Recent Developments/Updates
Table 165. Key Raw Materials Lists
Table 166. Raw Materials Key Suppliers Lists
Table 167. Non-Insulin Hypoglycemic Drug Distributors List
Table 168. Non-Insulin Hypoglycemic Drug Customers List
Table 169. Non-Insulin Hypoglycemic Drug Market Trends
Table 170. Non-Insulin Hypoglycemic Drug Market Drivers
Table 171. Non-Insulin Hypoglycemic Drug Market Challenges
Table 172. Non-Insulin Hypoglycemic Drug Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Non-Insulin Hypoglycemic Drug
Figure 2. Global Non-Insulin Hypoglycemic Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Non-Insulin Hypoglycemic Drug Market Share by Type in 2022 & 2034
Figure 4. Sulfonylureas Product Picture
Figure 5. Meglitinides Product Picture
Figure 6. Biguanides Product Picture
Figure 7. Thiazolidinediones Product Picture
Figure 8. Alpha Glucosidase Inhibitors Product Picture
Figure 9. Others Product Picture
Figure 10. Global Non-Insulin Hypoglycemic Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 11. Global Non-Insulin Hypoglycemic Drug Market Share by Application in 2022 & 2034
Figure 12. Hospital Pharmacies
Figure 13. Retail Pharmacies
Figure 14. Global Non-Insulin Hypoglycemic Drug Revenue, (US$ Million), 2024 VS 2022 VS 2034
Figure 15. Global Non-Insulin Hypoglycemic Drug Market Size (2024-2034) & (US$ Million)
Figure 16. Global Non-Insulin Hypoglycemic Drug Sales (2024-2034) & (K Units)
Figure 17. Global Non-Insulin Hypoglycemic Drug Average Price (US$/Unit) & (2024-2034)
Figure 18. Non-Insulin Hypoglycemic Drug Report Years Considered
Figure 19. Non-Insulin Hypoglycemic Drug Sales Share by Manufacturers in 2022
Figure 20. Global Non-Insulin Hypoglycemic Drug Revenue Share by Manufacturers in 2022
Figure 21. The Global 5 and 10 Largest Non-Insulin Hypoglycemic Drug Players: Market Share by Revenue in 2022
Figure 22. Non-Insulin Hypoglycemic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 23. Global Non-Insulin Hypoglycemic Drug Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Figure 24. North America Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2024-2034)
Figure 25. North America Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2024-2034)
Figure 26. United States Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 27. Canada Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 28. Europe Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2024-2034)
Figure 29. Europe Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2024-2034)
Figure 30. Germany Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 31. France Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 32. U.K. Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 33. Italy Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 34. Russia Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 35. Asia Pacific Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2024-2034)
Figure 36. Asia Pacific Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2024-2034)
Figure 37. China Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 38. Japan Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 39. South Korea Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 40. India Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 41. Australia Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 42. China Taiwan Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 43. Southeast Asia Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 44. Latin America Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2024-2034)
Figure 45. Latin America Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2024-2034)
Figure 46. Mexico Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 47. Brazil Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 48. Argentina Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 49. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2024-2034)
Figure 50. Middle East & Africa Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2024-2034)
Figure 51. Turkey Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 52. Saudi Arabia Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 53. UAE Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 54. Global Sales Market Share of Non-Insulin Hypoglycemic Drug by Type (2024-2034)
Figure 55. Global Revenue Market Share of Non-Insulin Hypoglycemic Drug by Type (2024-2034)
Figure 56. Global Non-Insulin Hypoglycemic Drug Price (US$/Unit) by Type (2024-2034)
Figure 57. Global Sales Market Share of Non-Insulin Hypoglycemic Drug by Application (2024-2034)
Figure 58. Global Revenue Market Share of Non-Insulin Hypoglycemic Drug by Application (2024-2034)
Figure 59. Global Non-Insulin Hypoglycemic Drug Price (US$/Unit) by Application (2024-2034)
Figure 60. Non-Insulin Hypoglycemic Drug Value Chain
Figure 61. Non-Insulin Hypoglycemic Drug Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed